Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bariatric surgery helps women with future pregnancies

This article was originally published in The Gray Sheet

Executive Summary

Report by the Agency for Healthcare Research and Quality (AHRQ) published in the Nov. 19 Journal of the American Medical Association suggests that fertility improves in women of reproductive age following bariatric surgical procedures, based on a review of literature on open and laparoscopic gastric bypass, laparoscopic adjustable banding, biliopancreatic diversion and vertical-banded gastroplasty. Pregnancy-related risks of hypertension and diabetes may decline in patients whose morbid obesity is resolved with bariatric surgery prior to pregnancy, the research indicates. The review also found "no evidence that delivery complications are higher in post-surgery pregnancies," and that nutritional deficiencies for mother and child are minimal post-surgery, "as long as adequate maternal nutrition and vitamin supplementation are maintained." According to AHRQ, women aged 18-45 accounted for about half of the patients who underwent bariatric surgery between 1998 and 2005

You may also be interested in...



Organon And Henlius Complete Phase III For Denosumab

Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.

Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims

Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel